Viral diagnostics and antiviral therapy in hematopoietic stem cell transplantation

Current Pharmaceutical Design

Volumn 14, Issue 20, 2008, Pages 1997-2010

  Anderson, Evan J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiviral Therapy; Gastrointestinal viruses; Hematopoietic Stem Cell Transplantation; Human metapneumovirus; Immunosuppression; Pathogens; Viral diseases

Indexed keywords

ACICLOVIR; AMANTADINE; ANTIVIRUS AGENT; CIDOFOVIR; CIPROFLOXACIN; FOSCARNET; GANCICLOVIR; HEPATITIS B VACCINE; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; LEFLUNOMIDE; MEASLES MUMPS RUBELLA VACCINE; NITAZOXANIDE; OSELTAMIVIR; PALIVIZUMAB; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBAVIRIN; RIMANTADINE; RISPERIDONE; RITUXIMAB; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VARICELLA ZOSTER VACCINE; VIDARABINE; ZANAMIVIR;

ADENOVIRUS; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; COMMUNITY; CONJUNCTIVITIS; CYSTITIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEALTH CARE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; HUMAN METAPNEUMOVIRUS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFLUENZA; LATENT PERIOD; MEASLES; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; PARAINFLUENZA VIRUS; PICORNAVIRUS; POLYMERASE CHAIN REACTION; POLYOMA VIRUS; PRIORITY JOURNAL; RECIPIENT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY VIRUS; REVIEW; RISK FACTOR; VARICELLA ZOSTER VIRUS; VIRAL GASTROENTERITIS; VIRUS CULTURE; VIRUS DETECTION; VIRUS INFECTION; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; GASTROINTESTINAL DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; RESPIRATORY TRACT INFECTIONS; VIRUS ACTIVATION; VIRUS DISEASES; VIRUS LATENCY;

EID: 52949145634     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208785061364     Document Type: Review

References (260)

1. Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380-9.
2. Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper PE, et al. Adenovirus infections following allogeneic stem cell transplantation: Incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100: 1619-27.
3. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-63.
4. Kampmann B, Cubitt D, Walls T, Naik P, Depala M, Samarasinghe S, et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol 2005; 130: 595-603.
5. Lion T, Baumgartinger R, Watzinger F, Matthes-Martin S, Suda M, Preuner S, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003; 102: 1114-20.
6. Moss P. Developments in the treatment of post-transplant viral disease. Best Pract Res Clin Haematol 2001; 14: 777-92.
7. Chakrabarti S, Collingham KE, Fegan CD, Pillay D, Milligan DW. Adenovirus infections following haematopoietic cell transplantation: Is there a role for adoptive immunotherapy? Bone Marrow Transplant 2000; 26: 305-7.
8. van Tol MJ, Claas EC, Heemskerk B, Veltrop-Duits LA, de Brouwer CS, van Vreeswijk T, et al. Adenovirus infection in children after allogeneic stem cell transplantation: Diagnosis, treatment and immunity. Bone Marrow Transplant 2005; 35(Suppl 1): S73-6.
9. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-44.
10. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood 1987; 69: 369-80.
11. Haddad E, Landais P, Friedrich W, Gerritsen B, Cavazzana-Calvo M, Morgan G, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: A European retrospective study of 116 patients. Blood 1998; 91: 3646-53.
12. Nichols WG, Erdman DD, Han A, Zukerman C, Corey L, Boeckh M. Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: Insights from molecular epidemiologic analysis. Biol Blood Marrow Transplant 2004; 10: 58-64.
13. Leruez-Ville M, Chardin-Ouachee M, Neven B, Picard C, Le Guinche I, Fischer A, et al. Description of an adenovirus A31 outbreak in a paediatric haematology unit. Bone Marrow Transplant 2006; 38: 23-8.
14. Taylor GS, Vipond IB, Caul EO. Molecular epidemiology of outbreak of respiratory syncytial virus within bone marrow transplantation unit. J Clin Microbiol 2001; 39: 801-3.
15. Harrington RD, Hooton TM, Hackman RC, Storch GA, Osborne B, Gleaves CA, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992; 165: 987-93.
16. Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med 2006; 355: 1303-5.
17. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598-603.
18. Ison MG. Respiratory viral infections in transplant recipients. Antivir Ther 2007; 12: 627-38.
19. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from sero-positive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273-82.
20. Grow WB, Moreb JS, Roque D, Manion K, Leather H, Reddy V, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29: 15-9.
21. Flomenberg P, Babbitt J, Drobyski WR, Ash RC, Carrigan DR, Sedmak GV, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994; 169: 775-81.
22. Rabalais GP, Stout GG, Ladd KL, Cost KM. Rapid diagnosis of respiratory viral infections by using a shell vial assay and monoclonal antibody pool. J Clin Microbiol 1992; 30: 1505-8.
23. Espy MJ, Hierholzer JC, Smith TF. The effect of centrifugation on the rapid detection of adenovirus in shell vials. Am J Clin Pathol 1987; 88: 358-60.
24. Englund JA, Boeckh M, Kuypers J, Nichols WG, Hackman RC, Morrow RA, et al. Brief communication: Fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med 2006; 144: 344-9.
25. Gerna G, Campanini G, Rognoni V, Marchi A, Rovida F, Piralla A, et al. Correlation of viral load as determined by real-time RT-PCR and clinical characteristics of respiratory syncytial virus lower respiratory tract infections in early infancy. J Clin Virol 2008; 41: 45-8.
26. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006; 43: 331-9.
27. Moss PA, Cobbold M, Craddock C. The cellular immunotherapy of viral infection. Transfus Med 2003; 13: 405-15.
28. Khanna N, Widmer AF, Decker M, Steffen I, Halter J, Heim D, et al. Respiratory syncytial virus infection in patients with hematological diseases: Single-center study and review of the literature. Clin Infect Dis 2008; 46: 402-12.
29. Claas EC, Schilham MW, de Brouwer CS, Hubacek P, Echavarria M, Lankester AC, et al. Internally controlled real-time PCR monitoring of adenovirus DNA load in serum or plasma of transplant recipients. J Clin Microbiol 2005; 43: 1738-44.
30. Schilham MW, Claas EC, van Zaane W, Heemskerk B, Vossen JM, Lankester AC, et al. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin Infect Dis 2002; 35: 526-32.
31. Leruez-Ville M, Minard V, Lacaille F, Buzyn A, Abachin E, Blanche S, et al. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis 2004; 38: 45-52.
32. Shepp DH, Dandliker PS, Flournoy N, Meyers JD. Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients. Transplantation 1987; 43: 654-8.
33. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 1984; 100: 823-8.
34. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981; 305: 63-7.
35. Magaret AS, Wald A, Huang ML, Selke S, Corey L. Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa. J Clin Microbiol 2007; 45: 1618-20.
36. Kimberlin DW. Diagnosis of herpes simplex virus in the era of polymerase chain reaction. Pediatr Infect Dis J 2006; 25: 841-2.
37. Kimberlin D. Herpes simplex virus, meningitis and encephalitis in neonates. Herpes 2004; 11(Suppl 2): 65A-76A.
38. Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers JD. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: A double-blind trial. Ann Intern Med 1982; 96: 265-9.
39. Meyers JD, Wade JC, Mitchell CD, Saral R, Lietman PS, Durack DT, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982; 73: 229-35.
40. Wade JC, Day LM, Crowley JJ, Meyers JD. Recurrent infection with herpes simplex virus after marrow transplantation: Role of the specific immune response and acyclovir treatment. J Infect Dis 1984; 149: 750-6.
41. Hoglund M, Ljungman P, Weller S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother 2001; 47: 855-61.
42. Eisen D, Essell J, Broun ER, Sigmund D, DeVoe M. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant 2003; 31: 51-5.
43. Dignani MC, Mykietiuk A, Michelet M, Intile D, Mammana L, Desmery P, et al. Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation. Bone Marrow Transplant 2002; 29: 263-7.
44. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007; 196: 266-70.
45. Fields BN, Knipe DM, Howley PM. Fields' virology. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2007.
46. Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: Risk factors and prognostic significance. J Infect Dis 2000; 181: 2055-8.
47. Frangoul H, Wills M, Crossno C, Engel M, Domm J. Acyclovir-resistant herpes simplex virus pneumonia post-unrelated stem cell transplantation: a word of caution. Pediatr Transplant 2007; 11: 942-4.
48. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91: 119-26.
49. Wingard JR, Chen DY, Burns WH, Fuller DJ, Braine HG, Yeager AM, et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988; 71: 1432-7.
50. Ljungman P. Prevention and treatment of viral infections in stem cell transplant recipients. Br J Haematol 2002; 118: 44-57.
51. Nichols WG. Management of infectious complications in the hematopoietic stem cell transplant recipient. J Intensive Care Med 2003; 18: 295-312.
52. Boeckh M, Gooley TA, Reusser P, Buckner CD, Bowden RA. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 1995; 172: 939-43.
53. Einsele H, Ehninger G, Steidle M, Fischer I, Bihler S, Gerneth F, et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 1672-8.
54. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-88.
55. Castagnola E, Cappelli B, Erba D, Rabagliati A, Lanino E, Dini G. Cytomegalovirus infection after bone marrow transplantation in children. Hum Immunol 2004; 65: 416-22.
56. Craddock C, Szydlo RM, Dazzi F, Olavarria E, Cwynarski K, Yong A, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: The case for tailored graft-versus-host disease prophylaxis. Br J Haematol 2001; 112: 228-36.
57. Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95: 2240-5.
58. Roenhorst HW, Kallenberg CG, The TH. The cellular immune response to cell-associated and cell-free cytomegalovirus (CMV) antigens after primary CMV-infection in non-immunocompromised hosts: Development and maintenance of CMV-latency and its influence on immunocompetence. Clin Exp Immunol 1988; 74: 326-32.
59. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-20.
60. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601-7.
61. Caliendo AM, St George K, Kao SY, Allega J, Tan BH, LaFontaine R, et al. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: Clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J Clin Microbiol 2000; 38: 2122-7.
62. Aitken C, Barrett-Muir W, Millar C, Templeton K, Thomas J, Sheridan F, et al. Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation. J Clin Microbiol 1999; 37: 2804-7.
63. Caliendo AM, St George K, Allega J, Bullotta AC, Gilbane L, Rinaldo CR. Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays. J Clin Microbiol 2002; 40: 1581-6.
64. Humar A, Gregson D, Caliendo AM, McGeer A, Malkan G, Krajden M, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999; 68: 1305-11.
65. Humar A, O'Rourke K, Lipton J, Messner H, Meharchand J, Mahony J, et al. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation. Bone Marrow Transplant 1999; 23: 45-51.
66. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186: 829-33.
67. Caliendo AM, Schuurman R, Yen-Lieberman B, Spector SA, Andersen J, Manjiry R, et al. Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma. J Clin Microbiol 2001; 39: 1334-8.
68. Yerly S, Perrin L, Van Delden C, Schaffer S, Thamm S, Wunderli W, et al. Cytomegalovirus quantification in plasma by an automated real-time PCR assay. J Clin Virol 2007; 38: 298-303.
69. Ljungman P, Engelhard D, Link H, Biron P, Brandt L, Brunet S, et al. Treatment of interstitial pneumonitis due to cytomegalovirus European Bone Marrow Transplant Group. Clin Infect Dis 1992; 14: 831-5.
70. Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J, et al. Cytomegaloviras pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109: 777-82.
71. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109: 783-8.
72. Ljungman P, Cordornnier C, Einsele H, Bender-Gotze C, Bosi A, Dekker A, et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: A report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 1998; 21: 473-6.
73. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991; 324: 1005-11.
74. Winston,DJ, Baden LR, Gabriel DA, Emmanouilides C, Shaw LM, Lange WR, et al. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stern cell transplant patients with graft-versus-host disease of the gastrointestinal tract, Biol Blood Marrow Transplant 2006; 12: 635-40.
75. Einsele H, Reusser P, Bornhauser M, Kalhs P, Ehninger G, Hebart H, et al. Oral valganciclovir leads to higher exposure to gancielovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006; 107: 3002-8.
76. Machado CM, Dulley FL, Boas LS, Castelli JB, Macedo MC, Silva RL, et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant 2000; 26: 413-7.
77. Bacigalupo A, Bregante S, Tedone E, Isaza A, Van Lint MT, Moto F, et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation 1996; 62: 376-80.
78. Mattes FM, Hainsworth EG, Geretti AM, Nebbia G, Prentice G, Potter M, et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 2004; 189: 1355-61.
79. Ljungman P, Deliliers GL, Platzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001; 97: 388-92.
80. Meyers JD, Leszczynski J, Zaia JA, Flournoy N, Newton B, Snydman DR, et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 1983; 98: 442-6.
81. Ruutu T, Ljungman P, Brinch L, Lenhoff S, Lonnqvist B, Ringden O, et al. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Bone Marrow Transplant 1997; 19: 233-6.
82. Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: Appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 117-30.
83. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705-12.
84. Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: Clinical outcome and effect on subsequent immume recovery. Biol Blood Marrow Transplant 1996; 2: 44-53.
85. Wade JC, Hintz M, McGuffin R, Springmeyer SC, Connor JD, Meyers JD. Treatment of cytomegalovirus pneumonia with highdose acyclovir. Am J Med 1982; 73: 249-56.
86. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied NJ, Camara R, et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. Bone Marrow Transplant 1997; 19: 129-33.
87. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied N, Fernandez Ranada JM, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749-53.
88. Winston DJ, Yeager AM, Chaudrasekar PH, Snydman DR, Petersen FB, Territo MC. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003; 36: 749-58.
89. Ljungman P, de La Camara R, Milpied N, Volin L, Russell CA, Crisp A, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002; 99: 3050-6.
90. Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy, for CMV infection. Bone Marrow Transplant 2000; 25: 757-63.
91. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogencic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118: 179-84.
92. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovitus pp65 antigenemia-guided early treatment with ganciclovir versus gancielovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 1996; 88: 4063-71.
93. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-8.
94. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogencic hematopoietic stem cell transplants: Importance of viral load and T-cell immunity. Blood 2003; 101: 407-14.
95. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-9.
96. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, et al. Randomized multicenter trial of foscamet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogencic stem cell transplantation. Blood 2002; 99: 1159-64.
97. Bacigalupo A, Tedone E, Van Lint MT, Trespi G, Lonngren M, Sanna MA, et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994; 13: 783-8.
98. Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG, et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004; 42: 1142-8.
99. Peggs KS, Preiser W, Kottaridis PD, McKeag N, Brink NS, Tedder RS, et al. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol 2000, 111: 782-90.
100. Wolf DG, Lurain NS, Zuckerman T, Hoffman R, Satinger J, Honigman A, et al. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 2003; 101: 463-5.
101. Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 851-6.
102. van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006; 37: 693-8.
103. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152: 1172-81.
104. Atkinson K, Meyers JD, Storb R, Prentice RL, Thomas ED. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation 1980; 29: 47-50.
105. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: Incidence, risk factors and complications. Bone Marrow Transplant 1994; 13: 277-83.
106. Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R. Herpes zoster infection after autologous bone marrow transplantation. Blood 1989; 74: 1424-7.
107. Kawasaki H, Takayama J, Ohira M. Herpes zoster infection after bone marrow transplantation in children. J Pediatr 1996; 128: 353-6.
108. Webster A, Grint P, Brenner MK, Prentice HG, Griffiths PD. Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster. J Med Virol 1989; 27: 117-9.
109. Schmutzhard J, Merete Riedel H, Zweygberg Wirgart B, Grillner L. Detection of herpes simplex virus type 1, herpes simplex virus type 2 and varicella-zoster virus in skin lesions. Comparison of real-time PCR, nested PCR and virus isolation. J Clin Virol 2004; 29: 120-6.
110. Balfour HH Jr, Bean B, Laskin OL, Ambinder RF, Meyers JD, Wade JC, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308: 1448-53.
111. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Longterm acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation->a randomized double-blind placebo-controlled study. Blood 2006; 107: 1800-5.
112. Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000; 25: 657-64.
113. Sempere A, Sanz GF, Senent L, de la Rubia J, Jarque I, Lopez F, et al. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant 1992; 10: 495-8.
114. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1992; 165: 119-26.
115. Reusser P, Cordonnier C, Einsele H, Engelhard D, Link D, Locasciulli A, et al. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17: 813-7.
116. Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 1997; 20: 381-3.
117. Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997; 176: 578-85.
118. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347: 26-34.
119. A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006; 55: 209-10.
120. Funk GA, Gosert R, Hirsch HH. Viral dynamics in transplant patients: implications for disease. Lancet Infect Dis 2007; 7: 460-72.
121. Gerritsen EJ, Stam ED, Hermans J, van den Berg H, Haraldsson A, van Tol MJ, et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996; 18: 377-82.
122. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-9.
123. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lympho-proliferative disorders. Annu Rev Med 2005; 56: 29-44.
124. Annels NE, Kalpoe JS, Bredius RG, Claas EC, Kroes AC, Hislop AD, et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 2006; 42: 1743-8.
125. Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmsen MC, The TH, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165-71.
126. Greenfield HM, Gharib MI, Turner AJ, Guiver M, Carr T, Will AM, et al. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: Can it successfully predict outcome and guide intervention? Pediatr Blood Cancer 2006; 47: 200-5.
127. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979-81.
128. Aalto SM, Juvonen E, Tarkkanen J, Volin L, Haario H, Ruutu T, et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis 2007; 45: 1305-9.
129. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364-9.
130. Gruhn B, Meerbach A, Hafer R, Zell R, Wutzler P, Zintl F. Preemptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31: 1023-5.
131. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502-5.
132. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100: 2257-9.
133. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
134. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-91.
135. Kadakia MP, Rybka WB, Stewart JA, Patton JL, Stamey FR, Elsawy M, et al. Human herpesvirus 6: Infection and disease following autologous and allogeneic bone marrow transplantation. Blood 1996; 87: 5341-54.
136. Ljungman P, Wang FZ, Clark DA, Emery VC, Remberger M, Ringden O, et al. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol 2000; 111: 774-81.
137. Yoshikawa T. Human herpesvirus 6 infection in hematopoietic stem cell transplant patients. Br J Haematol 2004; 124: 421-32.
138. Yoshikawa T. Significance of human herpesviruses to transplant recipients. Curr Opin Infect Dis 2003; 16: 601-6.
139. Wang FZ, Larsson K, Linde A, Ljungman P. Human herpesvirus 6 infection and cytomegalovirus-specific lymphoproliferative responses in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2002; 30: 521-6.
140. Wang FZ, Dahl H, Linde A, Brytting M, Ehrnst A, Ljungman P. Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Blood 1996; 88: 3615-20.
141. Ljungman P, Singh N. Human herpesvirus-6 infection in solid organ and stem cell transplant recipients. J Clin Virol 2006; 37 (Suppl 1): S87-91.
142. Chan PK, Peiris JS, Yuen KY, Liang RH, Lau YL, Chen FE, et al. Human herpesvirus-6 and human herpesvirus-7 infections in bone marrow transplant recipients. J Med Virol 1997; 53: 295-305.
143. Gentile G, Capobianchi A, Volpi A, Palu G, Pica F, Calistri A, et al. Human herpesvirus 8 DNA in serum during seroconversion in allogeneic bone marrow transplant recipients. J Natl Cancer Inst 2005; 97: 1008-11.
144. Luppi M, Barozzi P, Schulz TF, Setti G, Staskus K, Trovato R, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med 2000; 343: 1378-85.
145. Bruno B, Sorasio R, Barozzi P, Vieira J, Omede P, Giaretta F, et al. Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myeloablative allogeneic haematopoietic transplantation. Eur J Haematol 2006; 76: 342-7.
146. Engels EA, Atkinson JO, Graubard BI, McQuillan GM, Gamache C, Mbisa G, et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis 2007; 196: 199-207.
147. Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, et al. Respiratory virus infections after stem cell transplantation: A prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001; 28: 479-84.
148. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.
149. Ison MG, Hayden FG. Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr Opin Infect Dis 2002; 15: 355-67.
150. Ahluwalia G, Embree J, McNicol P, Law B, Hammond GW. Comparison of nasopharyngeal aspirate and nasopharyngeal swab specimens for respiratory syncytial virus diagnosis by cell culture, indirect immunofluorescence assay, and enzyme-linked immunosorbent assay. J Clin Microbiol 1987; 25: 763-7.
151. Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 32: 1085-8.
152. Hindiyeh M, Hillyard DR, Carroll KC. Evaluation of the Prodesse Hexaplex multiplex PCR assay for direct detection of seven respiratory viruses in clinical specimens. Am J Clin Pathol 2001; 116: 218-24.
153. Barton TD, Blumberg EA. Viral pneumonias other than cytomegalovirus in transplant recipients. Clin Chest Med 2005; 26: 707-20, viii.
154. El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe respiratory syncytial virus disease in children with cancer: The importance of lymphopenia and young age. Pediatrics 2008; 121: 235-43.
155. Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: The Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001; 7 Suppl: 11S-15S.
156. McCarthy AJ, Kingman HM, Kelly C, Taylor GS, Caul EO, Grier D, et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. Bone Marrow Transplant 1999; 24: 1315-22.
157. Jones BL, Clark S, Curran ET, McNamee S, Horne G, Thakker B, et al. Control of an outbreak of respiratory syncytial virus infection in immunocompromised adults. J Hosp Infect 2000; 44: 53-7.
158. Garcia R, Raad I, Abi-Said D, Bodey G, Champlin R, Tarrand J, et al. Nosocomial respiratory syncytial virus infections: Prevention and control in bone marrow transplant patients. Infect Control Hosp Epidemiol 1997; 18: 412-6.
159. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. Engl J Med 1993; 329: 1524-30.
160. Cortez K, Murphy BR, Almeida KN, Beeler J, Levandowski RA, Gill VJ, et al. Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation. J Infect Dis 2002; 186: 834-8.
161. Englund JA, Sullivan CJ, Jordan MC, Dehner LP, Vercellotti GM, Balfour HH, Jr. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med 1988; 109: 203-8.
162. Hertz MI, Englund JA, Snover D, Bitterman PB, McGlave PB. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: A clinical approach and review of the literature. Medicine (Baltimore) 1989; 68: 269-81.
163. Whimbey E, Champlin RE, Englund JA, Mirza NQ, Piedra PA, Goodrich JM, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 393-9.
164. Peck AJ, Englund JA, Kuypers J, Guthrie KA, Corey L, Morrow R, et al. Respiratory virus infection among hematopoietic cell transplant recipients: Evidence for asymptomatic parainfluenza virus infection. Blood 2007; 110: 1681-8.
165. Lewinsohn DM, Bowden RA, Mattson D, Crawford SW. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother 1996; 40: 2555-7.
166. Ghosh S, Champlin RE, Englund J, Giralt SA, Rolston K, Raad I, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000; 25: 751-5.
167. Ghosh S, Champlin RE, Ueno NT, Anderlini P, Rolston K, Raad I, et al. Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: Combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant 2001; 28: 271-5.
168. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001; 184: 350-4.
169. Aslan T, Fassas AB, Desikan R, Siegel D, Munshi N, Mehta J, et al. Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy. Bone Marrow Transplant 1999; 24: 505-9.
170. Anaissie EJ, Mahfouz TH, Aslan T, Pouli A, Desikan R, Fassas A, et al. The natural history of respiratory syncytial virus infection in cancer and transplant patients: Implications for management. Blood 2004; 103: 1611-7.
171. Peck AJ, Corey L, Boeckh M. Pretransplantation respiratory syncytial virus infection: Impact of a strategy to delay transplantation. Clin Infect Dis 2004; 39: 673-80.
172. Whimbey E, Elting LS, Couch RB, Lo W, Williams L, Champlin RE, et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994; 13: 437-40.
173. Whimbey E, Champlin RE, Couch RB, Englund JA, Goodrich JM, Raad I, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996; 22: 778-82.
174. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: Risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39: 1300-6.
175. Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26: 1418-24.
176. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: Detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995; 172: 1352-5.
177. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55: 1-42.
178. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295: 891-4.
179. Johny AA, Clark A, Price N, Carrington D, Oakhill A, Marks DI. The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29: 113-5.
180. Machado CM, Boas LS, Mendes AV, da Rocha IF, Sturaro D, Dulley FL, et al. Use of Oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant 2004; 34: 111-4.
181. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353: 1363-73.
182. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240-6.
183. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004; 103: 199-203.
184. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet 2004; 364: 759-65.
185. Vu D, Peck AJ, Nichols WG, Varley C, Englund JA, Corey L, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: A retrospective case-control study. Clin Infect Dis 2007; 45: 187-93.
186. Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciu H, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993; 11: 1-5.
187. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49: 1-125.
188. Lewis VA, Champlin R, Englund J, Couch R, Goodrich JM, Rolston K, et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis 1996; 23: 1033-7.
189. Wendt CH, Weisdorf DJ, Jordan MC, Balfour HH Jr, Hertz MI. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med 1992; 326: 921-6.
190. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: Risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98: 573-8.
191. Elizaga J, Olavarria E, Apperley J, Goldman J, Ward K. Parainfluenza virus 3 infection after stem cell transplant: Relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis 2001; 32: 413-8.
192. Sparrelid E, Ljungman P, Ekelof-Andstrom E, Aschan J, Ringden O, Winiarski J, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997; 19: 905-8.
193. Chakrabarti S, Collingham KE, Holder K, Oyaide S, Pillay D, Milligan DW. Parainfluenza virus type 3 infections in hematopoetic stem cell transplant recipients: Response to ribavirin therapy. Clin Infect Dis 2000; 31: 1516-8.
194. Hohenthal U, Nikoskelainen J, Vainionpaa R, Peltonen R, Routamaa M, Itala M, et al. Parainfluenza virus type 3 infections in a hematology unit. Bone Marrow Transplant 2001; 27: 295-300.
195. Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003; 60: 51-9.
196. Ghosh S, Champlin R, Couch R, Englund J, Raad I, Malik S, et al. Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis 1999; 29: 528-32.
197. Ison MG, Hayden FG, Kaiser L, Corey L, Boeckh M. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 2003; 36: 1139-43.
198. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: The Christie hospital experience. Bone Marrow Transplant 2003; 32: 73-7.
199. Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: Results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003; 36: 1523-32.
200. Gonzalez Y, Martino R, Badell I, Pardo N, Sureda A, Brunet S, et al. Pulmonary enterovirus infections in stem cell transplant recipients. Bone Marrow Transplant 1999; 23: 511-3.
201. Hierholzer JC. Adenoviruses in the immunocompromised host. Clin Microbiol Rev 1992; 5: 262-74.
202. Chakrabarti S, Milligan DW, Moss PA, Mautner V. Adenovirus infections in stem cell transplant recipients: Recent developments in understanding of pathogenesis, diagnosis and management. Leuk Lymphoma 2004; 45: 873-85.
203. Blanke C, Clark C, Broun ER, Tricot G, Cunningham I, Cornetta K, et al. Evolving pathogens in allogeneic bone marrow transplantation: increased fatal adenoviral infections. Am J Med 1995; 99: 326-8.
204. Howard DS, Phillips IG, Reece DE, Munn RK, Henslee-Downey J, Pittard M, et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 1999; 29: 1494-501.
205. Shields AF, Hackman RC, Fife KH, Corey L, Meyers JD. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 1985; 312: 529-33.
206. La Rosa AM, Champlin RE, Mirza N, Gajewski J, Giralt S, Rolston KV, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001; 32: 871-6.
207. Lewis P, Schmidt M, Thomas A, Cieslak P, Grenz L, Kendall B, et al. Adenovirus 14: A new cause of severe community-acquired pneumonia (LB-5). IDSA Annual Meeting. San Diego, California., 2007.
208. Tate J, Widdowson M, Anderson L, Lott L, Lu X, Bunning M. Adenovirus 14 Infection in Basic Military Trainees (LB-14). IDSA Annual Conference. San Diego, California., 2007.
209. Acute respiratory disease associated with adenovirus serotype 14 - four states, 2006-2007. MMWR Morb Mortal Wkly Rep 2007; 56: 1181-4.
210. Anderson EJ, Guzman-Cottrill JA, Kletzel M, Thormann K, Sullivan C, Zheng X, et al. High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant 2008; 12: 219-27.
211. Baldwin A, Kingman H, Darville M, Foot AB, Grier D, Cornish JM, et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant 2000; 26: 1333-8.
212. Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32: 1290-7.
213. Runde V, Ross S, Trenschel R, Lagemann E, Basu O, Renzing-Kohler K, et al. Adenoviral infection after allogeneic stem cell transplantation (SCT): Report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. Bone Marrow Transplant 2001; 28: 51-7.
214. Bruno B, Gooley T, Hackman RC, Davis C, Corey L, Boeckh M. Adenovirus infection in hematopoietic stem cell transplantation: Effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant 2003; 9: 341-52.
215. Ljungman P, Ribaud P, Eyrich M, Matthes-Martin S, Einsele H, Bleakley M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: A survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31: 481-6.
216. Neofytos D, Ojha A, Mookerjee B, Wagner J, Filicko J, Ferber A, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007; 13: 74-81.
217. Erard V, Huang ML, Ferrenberg J, Nguy L, Stevens-Ayers TL, Hackman RC, et al. Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: Viral load as a marker for invasive disease. Clin Infect Dis 2007; 45: 958-65.
218. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 388-94.
219. Van Doomum GJ, De Jong JC. Rapid shell vial culture technique for detection of enteroviruses and adenoviruses in fecal specimens: comparison with conventional virus isolation method. J Clin Microbiol 1998; 36: 2865-8.
220. August MJ, Warford AL. Evaluation of a commercial monoclonal antibody for detection of adenovirus antigen. J Clin Microbiol 1987; 25: 2233-5.
221. Hierholzer JC, Johansson KH, Anderson LJ, Tsou CJ, Halonen PE. Comparison of monoclonal time-resolved fluoroimmunoassay with monoclonal capture-biotinylated detector enzyme immunoassay for adenovirus antigen detection. J Clin Microbiol 1987; 25: 1662-7.
222. Lehtomaki K, Julkunen I, Sandelin K, Salonen J, Virtanen M, Ranki M, et al. Rapid diagnosis of respiratory adenovirus infections in young adult men. J Clin Microbiol 1986; 24: 108-11.
223. Ishida H, Shin-Nakai N, Yoshihara T, Teramura T, Imamura T, Mukouyama A, et al. Invasive adenoviral infection in a recipient of unrelated bone marrow transplantation: Problems with diagnostic PCR. Pediatr Blood Cancer 2005; 44: 416-9.
224. Walls T, Hawrami K, Ushiro-Lumb I, Shingadia D, Saha V, Shankar AG. Adenovirus infection after pediatric bone marrow transplantation: Is treatment always necessary? Clin Infect Dis 2005; 40: 1244-9.
225. Chakrabarti S, Collingham KE, Fegan CD, Milligan DW. Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy. Bone Marrow Transplant 1999; 23: 1209-11.
226. Gavin PJ, Katz BZ. Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics 2002; 110: E9.
227. Lankester AC, Heemskerk B, Claas EC, Schilham MW, Beersma MF, Bredius RG, et al. Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin Infect Dis 2004; 38: 1521-5.
228. Morfin F, Dupuis-Girod S, Mundweiler S, Falcon D, Carrington D, Sedlacek P, et al. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther 2005; 10: 225-9.
229. Muller WJ, Levin MJ, Shin YK, Robinson C, Quinones R, Malcolm J, et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis 2005; 41: 1812-6.
230. Yusuf U, Hale GA, Carr J, Gu Z, Benaim E, Woodard P, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006; 81: 1398-404.
231. Kazory A, Singapuri S, Wadhwa A, Ejaz AA. Simultaneous development of Fanconi syndrome and acute renal failure associated with cidofovir. J Antimicrob Chemother 2007; 60: 193-4.
232. Polis MA, Spooner KM, Baird BF, Manischewitz JF, Jaffe HS, Fisher PE, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 1995; 39: 882-6.
233. Nagafuji K, Aoki K, Henzan H, Kato K, Miyamoto T, Eto T, et al. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2004; 34: 909-14.
234. Hartline CB, Gustin KM, Wan WB, Ciesla SL, Beadle JR, Hostetler KY, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: Activity against adenovirus replication in vitro. J Infect Dis 2005; 191: 396-9.
235. Anderson EJ, Weber SG. Rotavirus infection in adults. Lancet Infect Dis 2004; 4: 91-9.
236. Yolken RH, Bishop CA, Townsend TR, Bolyard EA, Bartlett J, Santos GW, et al. Infectious gastroenteritis in bone-marrow-transplant recipients. N Engl J Med 1982; 306: 1010-2.
237. Florescu DF, Hill LA, McCartan MA, Grant W. Two cases of Norwalk virus enteritis following small bowel transplantation treated with oral human serum immunoglobulin. Pediatr Transplant 2008; 12: 372-5.
238. Rossignol JF, Abu-Zekry M, Hussein A, Santoro MG. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: Randomised double-blind placebo-controlled trial. Lancet 2006; 368: 124-9.
239. Rossignol JF, El-Gohary YM. Nitazoxanide in the treatment of viral gastroenteritis: A randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther 2006; 24: 1423-30.
240. Townsend TR, Bolyard EA, Yolken RH, Beschorner WE, Bishop CA, Burns WH, et al. Outbreak of Coxsackie A1 gastroenteritis: A complication of bone-marrow transplantation. Lancet 1982; 1: 820-3.
241. Apperley JF, Rice SJ, Bishop JA, Chia YC, Krausz T, Gardner SD, et al. Late-onset hemorrhagic cystitis associated with urinary excretion of polyomaviruses after bone marrow transplantation. Transplantation 1987; 43: 108-12.
242. Arthur RR, Shah KV, Baust SJ, Santos GW, Saral R. Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med 1986; 315: 230-4.
243. Dropulic LK, Jones RJ. Polyomavirus BK infection in blood and marrow transplant recipients. Bone Marrow Transplant 2008; 41: 11-8.
244. Erard V, Kim HW, Corey L, Limaye A, Huang ML, Myerson D, et al. BK DNA viral load in plasma: Evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood 2005; 106: 1130-2.
245. Wong AS, Chan KH, Cheng VC, Yuen KY, Kwong YL, Leung AY. Relationship of pretransplantation polyoma BK virus serologic findings and BK viral reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2007; 44: 830-7.
246. Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2005; 40: 528-37.
247. Randhawa PS. Anti-BK virus activity of ciprofloxacin and related antibiotics. Clin Infect Dis 2005; 41: 1366-7.
248. Bridges B, Donegan S, Badros A. Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantation. Am J Hematol 2006; 81: 535-7.
249. Held TK, Biel SS, Nitsche A, Kurth A, Chen S, Gelderblom HR, et al. Treatment of BK virus-associated hemorrhagic cystitis and simultaneous CMV reactivation with cidofovir. Bone Marrow Transplant 2000; 26: 347-50.
250. Savona MR, Newton D, Frame D, Levine JE, Mineishi S, Kaul DR. Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant. Bone Marrow Transplant 2007; 39: 783-7.
251. Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh FR, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant 2007; 39: 101-7.
252. Strasser SI, McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management. Blood 1999; 93: 1127-36.
253. Endo T, Sakai T, Fujimoto K, Yamamoto S, Takashima H, Haseyama Y, et al. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2001; 27: 433-6.
254. Jaffe D, Papadopoulos EB, Young JW, O'Reilly R J, Prockop S, Kernan NA, et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood 2006; 108: 2470-5.
255. Ljungman P, Andersson J, Aschan J, Bjorkstrand B, Hagglund H, Lonnqvist B, et al. Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Clin Infect Dis 1996; 23: 167-9.
256. Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: A review of 98 cases. Clin Infect Dis 2006; 43: 40-8.
257. Ljungman P, Fridell E, Lonnqvist B, Bolme P, Bottiger M, Gahrton G, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989; 159: 610-5.
258. Patel SR, Ortin M, Cohen BJ, Borrow R, Irving D, Sheldon J, et al. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis 2007; 44: 625-34.
259. Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7: 89-93.
260. Lum LG, Munn NA, Schanfield MS, Storb R. The detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood 1986; 67: 582-7.